During the past 3 years, the average EPS without NRI Growth Rate was 23.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 55.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 33.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Zevra Therapeutics was 68.40% per year. The lowest was -51.40% per year. And the median was 27.75% per year.
Competitive Comparison of Zevra Therapeutics's 3-Year EPS without NRI Growth Rate
For the Biotechnology subindustry, Zevra Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Zevra Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Zevra Therapeutics (NAS:ZVRA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Zevra Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
Thank you for viewing the detailed overview of Zevra Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Zevra Therapeutics (Zevra Therapeutics) Business Description
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your